Previous 10 | Next 10 |
WOBURN, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended September 30, 2021. The Company is a leader in proprietary non-invasive medical devices for the diagnosis and treatment of pain and neurol...
AAL,ABB,ALK,ALLE,ALLY,AN,BCS,BX,CROX,DGX,DHR,DOW,EEFT,EWBC,FAF,FCX,GPC,GTLS,HRI,IPG,IQV,KEY,LNN,LUV,MMC,OTCQB:NEXCF,OTCPK:NLLSF,NUE,NURO,PDS,POOL,RCI,SAFE,SAP,SCHN,SNA,SON,T,TPH,TRN,TSCO,UNP,VLO For Seeking Alpha's full earnings season calendar, click here. For further details see: ...
WOBURN, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has appointed Susan M. Bell as Senior Vice President, Population Health & Value Based Care. Ms. Bell will be responsible for growing the Company's DPNCheck ® business with ...
WOBURN, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2021 third quarter financial results before the opening of the market on October 21, 2021. The Company will host a conference call at 8:00 a.m., Eastern Time on Octob...
4 Biotech Stocks To Add To Your October 2021 Watchlist In good times and bad, people and investors alike often turn to the health care industry. In particular, biotech stocks remain viable plays in the stock market today, nonetheless. For starters, investors appear to be breathi...
WOBURN, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has submitted a De Novo request to the U.S. Food and Drug Administration (FDA) for Quell as a prescription treatment for the symptoms of fibromyalgia in adults. The Company received FDA...
WOBURN, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has joined the Center to Stream Healthcare In Place (C2SHIP) as an industry partner. C2SHIP is a U.S. National Science Foundation (NSF) funded consortium of leading academic cente...
Gainers: TransCode Therapeutics (NASDAQ:RNAZ) +62%, ReWalk Robotics (NASDAQ:RWLK) +34%, NeuroMetrix (NASDAQ:NURO) +15%, Summit Therapeutics (NASDAQ:SMMT) +13%, IM Cannabis (NASDAQ:IMCC) +11%. Losers: Eargo (NASDAQ:EAR) -69%, Onconova Therapeutics (...
MEDIROM Healthcare Technologies (NASDAQ:MRM) +77% on deal for ZACC Kabushiki Kaisha Digital Brands (NASDAQ:DBGI) +27%. TransCode Therapeutics (NASDAQ:RNAZ) +15% announces publication in cancer nanotechnology of preclinical data supporting therapeutic potential of TTX-MC138 in m...
NeuroMetrix is a medical devices company with three commercialized products. The Company says it was spun off from the Harvard-MIT Division of Health Sciences and Technology in 1996. The Company has active R&D programs to expand into new indications and improve existing techno...
News, Short Squeeze, Breakout and More Instantly...
WOBURN, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2024. The Company's mission is to reduce the impact of neurological disorders and pain syndromes through innovative non-invasive medica...
Bank of Georgia Group Plc (BDGSF) is expected to report for Q1 2024 iCad Inc. (ICAD) is expected to report for Q1 2024 Yasheng Group (HERB) is expected to report for Q1 2024 Bit Digital Inc. (BTBT) is expected to report $0.01 for Q1 2024 Estrella Immunopharma Inc. (ESLA) is expect...
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...